Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 69

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 69
---
 beneficial ownership of the above-mentioned entity may have changed between September 30, 2024 and February 15, 2025. The address for Blackrock is 50 Hudson Yards, New York, NY 10001.

(4) As of the close of business on September 30, 2024, (i) Biotechnology Value Fund, L.P. ( “BVF” ) beneficially owned 1,579,980 shares of common stock, (ii) Biotechnology Value Fund II, L.P. ( “BVF2” ) beneficially owned 1,287,256 shares of common stock and (iii) Biotechnology Value Trading Fund OS LP ( “Trading Fund OS” ) beneficially owned 150,248 shares of common stock. BVF I GP LLC ( “BVF GP” ), as the general partner of BVF, may be deemed to beneficially own the 1,579,980 shares of common stock beneficially owned by BVF. BVF II GP LLC ( “BVF2 GP” ), as the general partner of BVF2, may be deemed to beneficially own the 1,287,256 shares of common stock beneficially owned by BVF2. BVF Partners OS Ltd. (“ Partners OS” ), as the general partner of Trading Fund OS, may be deemed to beneficially own the 150,248 shares of common stock beneficially owned by Trading Fund OS. BVF GP Holdings LLC ( “BVF GPH” ), as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 2,867,236 shares of common stock beneficially owned in the aggregate by BVF and BVF2. BVF Partners L.P. ( “Partners” ), as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 3,075,907 shares of common stock beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the “Partners Managed Account” ), including 58,423 shares of common stock held in the Partners Managed Account. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 3,075,907 shares of common stock beneficially owned by Partners. Mark N. Lampert ( “Mr. Lampert” ), as a director